An interventional study of Bariatric surgery + goal directed medical therapy and Bariatric surgery in Obesity and Type 2 Diabetes, sponsored by Imperial College London. Recruiting at 1 site in Ireland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-08.
Sponsored by Imperial College London · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Obesity by Imperial College London — 5 open to participants now, 6 under way, none of them phase 3. Obesity · Imperial College London.
Among the 36 studies in Obesity by Imperial College London, this one is the 3rd largest by planned enrollment of the 27 interventional ones that give a count, is the only one that started in 2021, is one of 21 with no phase, and was the 32nd registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →5 of the 36 studies in Obesity by Imperial College London are open now, in 2 countries. Recruiting first, the newest first:
Imperial College London · Sites in United Kingdom
Ages 18–60 · Healthy volunteers
Imperial College London · Sites in United Kingdom
Ages 18–80 · Healthy volunteers
Imperial College London · Sites in United Kingdom
Ages 18–70 · Healthy volunteers
Imperial College London · Sites in United Kingdom
Ages 18–75
By country, each count listing its studies:
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 1
First in 2008; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 53 across the 27 interventional studies, 100 across the 9 observational. Of the 25 that completed or were terminated, 19 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
Imperial College London is the lead sponsor of 844 studies on the registry; 181 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.
1 of the studies in Obesity by Imperial College London that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04432025Imperial College LondonMedication Following Bariatric Surgery for Type 2 Diabetes Mellitus | 2027-04-01 |
Add it to your calendar (.ics) → With an account.
Among the 36 studies in Obesity by Imperial College London, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of this study is to investigate the continued usage of standard diabetes medications in the post operative period following bariatric surgery to determine whether this approach may improve long term diabetes control. At present, the standard of treatment in patients with type 2 diabetes is that all medication is stopped in the immediate postoperative period and only re-started if symptoms of diabetes re-emerge. Although a large proportion of patients with diabetes will initially go in to remission, 80% experience relapse within five years. This study is needed to determine whether continuing medications is not only safe but will improve long term outcomes for patients with diabetes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will undergo bariatric surgery- either roux en y gastric bypass or sleeve gastrectomy. Long term diabetes care will be under the supervision of their primary care provider/general practitioner
Procedure: Bariatric surgery
Patients will undergo bariatric surgery- either roux en y gastric bypass or sleeve gastrectomy and will have ongoing goal directed medical treatment for their T2DM, titrated to specific end points for BP, HbA1c and lipids.
Procedure: Bariatric surgery + goal directed medical therapy
Patients will undergo bariatric surgery (RYGB or SG) with goal directed medical therapy titrated to specific end points for BP, HbA1c and lipids
Patients will undergo bariatric surgery (RYGB or SG) with usual care for diabetes mellitus undertaken by their primary care provider/general practitioner
Proportion of patients in each group reaching the composite end point
BP\<130/80, HbA1c\<6.5%, LDL\<2.6mmol/L
Time frame: 5 years
Proportion of patients reaching end point for glycemic control
HbA1c\<6.5%
Time frame: 1 year
Change in body weight
Change in body weight from baseline (kg)
Time frame: 5 years
Change in BMI
Change in BMI from baseline (kg/m2)
Time frame: 5 years
Change in waist circumference
Change in waist circumference (cm)
Time frame: 5 years
Change in lipid control
Proportion of patients achieving good lipid control (LDL\<2.6mmol/L)
Time frame: 5 years
Change in glycaemic control
Change in long term glycaemic control(HbA1c)
Time frame: 5 years
Change in blood pressure
Proportion of patients achieving BP\<130/80mmHg
Time frame: 5 years
Change in liver function
Proportion of patients achieving normal liver function tests (ALT, GGT, ALP, AST)
Time frame: 5 years
Change in renal function
Proportion of patients with normal renal function (plasma Cr, eGFR)
Time frame: 5 years
Change in inflammatory markers
Reduction in CRP
Time frame: 5 years
Change in urine albumin: creatinine ratio
Proportion of patients in each group with a uACR\<30
Time frame: 5 years
Change in quality of life
Quality of life change as determined by SF-36 and MPH-H
Time frame: 5 years
Plan to share: Yes — The authors shall make data available to the scientific community with as few restrictions as feasible, ensuring anonymisation, while retaining exclusive use until the publication of major outputs.
Supporting information: Study protocol
Time frame: 6 months
Access criteria: Free access
Started Apr 2021 (actual). Primary completion is estimated for Apr 2027, 72 months after the start.
Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 72 months is above that.
Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.